CJC-1295 No DAC

About CJC-1295 No DAC

CJC-1295 No DAC (Modified GRF 1-29) is a synthetic 29-amino-acid version of growth hormone releasing hormone (GHRH) that's been engineered for better stability through four carefully chosen amino acid changes. Unlike its DAC counterpart, this variant doesn't have the drug affinity complex, which means it has a shorter half-life that mimics the natural pulsing patterns of GHRH release. The peptide works by binding to GHRH receptors on anterior pituitary somatotrophs, triggering the body's own growth hormone secretion through the cAMP-PKA signalling pathway. Researchers use it to study GH-axis regulation, metabolic processes, and age-related hormonal changes. Here's what preclinical studies have found: plasma GH levels shoot up significantly within 30 minutes of administration, with effects lasting 2-4 hours. Research has also shown enhanced protein synthesis markers and improved insulin-like growth factor-1 (IGF-1) expression in laboratory models. Our pharmaceutical-grade CJC-1295 No DAC comes as a lyophilised powder with ≥98% purity verified by HPLC analysis, molecular weight 3367.9 Da, and a comprehensive certificate of analysis. It's strictly for in vitro research applications only.

Research Applications

• Studied for its role in GHRH receptor binding and pulsatile somatotroph signalling in pituitary cell models.
• Investigated for association with downstream IGF-1 axis activation in preclinical rodent studies.
• Researched for its short half-life profile relative to DAC-modified analogues in pharmacokinetic studies.
• Examined for involvement in growth hormone release frequency and amplitude in in vitro pituitary slice models.

Research Mechanism — CJC-1295 No DAC

A simplified summary of what CJC-1295 No DAC is studied for in research models. For laboratory in-vitro use only.

1. 1

   Molecular target

   CJC-1295 No DAC has been investigated as an agonist of the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs. The modifications are studied for their role in resisting DPP-IV cleavage.

   • GHRH-R, a class B G-protein-coupled receptor
   • Aib substitutions reduce DPP-IV proteolysis
   • Pituitary somatotroph cell membrane binding
2. 2

   Investigated pathways

   Preclinical studies have explored Gs-coupled cAMP/PKA signalling downstream of GHRH-R engagement. Associated signalling involves pulsatile GH release.

   • Adenylate cyclase activation and cAMP elevation
   • PKA-mediated CREB phosphorylation in somatotrophs
   • Pulsatile GH secretion and hepatic IGF-1 transcription
3. 3

   Preclinical research applications

   Preclinical studies have investigated CJC-1295 No DAC in rodent pituitary models and cultured pituitary cells to characterise GH secretagogue pharmacology. Not approved for human use.

   • Rat primary pituitary cell GH-release assays
   • Murine pulsatile GH-secretion profiling
   • Hepatic IGF-1 mRNA expression studies

For research use only. CJC-1295 No DAC is not approved as a medicine in the UK and is not intended for human or veterinary administration. See the compliance page for full terms.